Patents Examined by Maury Audet
  • Patent number: 10800827
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 13, 2020
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Patent number: 10765748
    Abstract: In various aspects, embodiments of the present invention are directed to a series of multivalent dendrons containing a bioactive peptide domain and surface-binding catechol domains. In some embodiments, these multivalent dendrons were obtained through solid phase synthesis and have a strong binding affinity to metal oxide surfaces such as, TiO2, ZrO2, CeO2, and Fe3O4, SiO2, as well as other inorganic surfaces such as hydroxyapatite, silver, fluorapatite, calcium carbonate and gold. These catechol-bearing dendrons provide a fast and efficient method to functionalize a wide range of inorganic materials with bioactive peptides and have the potential to be used in coating orthopaedic implants and fixation devices.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: September 8, 2020
    Assignee: University of Akron
    Inventors: Matthew Becker, Wen Tang
  • Patent number: 10745444
    Abstract: A cyclopeptide is disclosed, which is represented by the following formula (I) or (I?): wherein R1 is defined in the specification. In addition, a pharmaceutical or cosmetic composition comprising the same and a method for preparing the same are also disclosed.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: August 18, 2020
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventor: Chien-Tien Chen
  • Patent number: 10745737
    Abstract: Methods, reagents, and kits for the reversible immobilization of glycoproteins to a solid support, the release and capture of a glycan portion of the glycoprotein, and the subsequent release and capture of the polypeptide portion of the glycoprotein are provided. The disclosure also provides suitable solid support materials, surface chemistries, and devices for use in the disclosed methods. The methods, reagents, kits, and devices provided herein are useful for the analysis of protein glycosylation, for example, in a diagnostic context, in the context of proteoglycomics, and in the context of producing glycosylated proteins for therapeutic purposes.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: August 18, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: Richard S. Lee, Hui Zhou
  • Patent number: 10738079
    Abstract: This disclosure relates to compositions for use in managing respiratory distress and related disorders. In certain embodiments, the disclosure relates to methods of treating or preventing respiratory distress comprising administering an effective amount of a pharmaceutical composition comprising peptides or agents disclosed herein to a subject in need thereof. In certain embodiments, the peptides or agents decrease the concentration of claudin-5 in cells and tissues of the lungs.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: August 11, 2020
    Assignee: Emory University
    Inventors: Michael Koval, Barbara Schlingmann
  • Patent number: 10723764
    Abstract: Anti-microbial peptides and methods of use are provided.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: July 28, 2020
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventor: Guangshun Wang
  • Patent number: 10695399
    Abstract: Two peptides that can selectively bind to SEVI and block the enhanced infectivity that results from the interaction of SEVI with HIV. The two peptides comprise the amino acid sequences FEEIVQEIEDFLENLV (SEQ. ID NO: 1) and GIGAVLEVLTTGLPALISWIEEEEQQ (SEQ. ID. NO: 2). The peptides may be administered topically, either alone or in combination with other prophylactics, agents, etc.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: June 30, 2020
    Assignee: SYRACUSE UNIVERSITY
    Inventor: Ivan V. Korendovych
  • Patent number: 10689428
    Abstract: We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of: SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQRRCMPLHSRVPFP (SEQ ID NO: 2), or a fragment, homologue, variant or derivative thereof, which polypeptide is capable of maintaining self-renewal and/or pluripotency of a stem cell.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 23, 2020
    Assignee: Agency For Science, Technology And Research
    Inventor: Bruno Reversade
  • Patent number: 10676509
    Abstract: Immobilizable antimicrobial compounds incorporating antimicrobial and/or antifouling components, as can be adhered to various device structures and components.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: June 9, 2020
    Assignee: Northwestern University
    Inventors: Phillip B. Messersmith, Annelise E. Barron, Andrea Statz, Nathaniel Chongslriwatana
  • Patent number: 10669313
    Abstract: Provided herein is a multitarget-directed bio-inorganic hybrid structure. The hybrid structure is based on carbon nanotubes, and includes: carbon nanotubes; and two or more peptides bound to a surface of the carbon nanotubes and each independently interacting with different target molecules.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: June 2, 2020
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Yong Beom Lim, Woo Jin Jeong
  • Patent number: 10662221
    Abstract: There is provided herein compounds of formula I, wherein R1 is H or linear or branched C1-C6 lower alkyl; R2 is H, linear or branched C1-C6 lower alkyl, or a proteinogenic amino acid side chain; R3 is H, linear or branched C1-C6 lower alkyl, or a proteinogenic amino acid side chain; R4 is —OH or —O—R5 wherein R5 is linear or branched C1-C6 lower alkyl; and each R6 is independently H or —CH3; or a pharmaceutically acceptable prodrug, salt, or ester thereof. Compositions containing said compounds, and uses thereof, are also provided.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: May 26, 2020
    Assignee: UNIVERSITY OF PRINCE EDWARD ISLAND
    Inventors: Krista Ann Gill, Fabrice Berrue, Russell Greig Kerr
  • Patent number: 10639346
    Abstract: The present invention derives from the finding that increased levels of Toll like receptor 4 (TLR4) is associated with liver failure and renal dysfunction and/or brain dysfunction and that by decreasing TLR4 levels in vivo, the kidney and brain consequences of liver disease that are precipitated by superimposed infection or inflammation may be reduced. Accordingly, the invention provides TLR4 antagonists for use in a method of treating an individual suffering from liver disease presenting with renal or brain dysfunction.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: May 5, 2020
    Assignee: Yaqrit Limited
    Inventors: Rajiv Jalan, Naina Shah
  • Patent number: 10610595
    Abstract: Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: April 7, 2020
    Assignee: SANOFI
    Inventors: Oliver Bley, Petra Loos, Bernd Bidlingmaier, Walter Kamm, Harald Berchtold
  • Patent number: 10611799
    Abstract: An anti-endotoxin polypeptide is provided. The anti-endotoxin polypeptide having the formula (I) A1-L-C1, wherein A1 and C1 independently is a short peptide with ?-helix, L is AGP (Ala-Gly-Pro) or a peptide bond, and the hydrophobicity of the hydrophobic terminus in the anti-endotoxin polypeptide is between about 0.425 and 0.765. The anti-endotoxin polypeptide of the invention can neutralize the lipopolysaccharide and has the low hemolysis and high salt resistance, simultaneously. The present invention also provides a method for design an anti-endotoxin polypeptide, the anti-endotoxic activity is adjusted through increasing and/or decreasing hydrophobicity of the hydrophobic terminal end.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: April 7, 2020
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Jya-Wei Cheng, Hung-Lun Chu, Ya-Han Chih, Hui-Yuan Yu
  • Patent number: 10610608
    Abstract: Targeted molecular imaging agents (TMIAs) are derived from coupling together pre-formed amino acids with imaging agents attached to their side chains. These peptide-based imaging agents may synthesized from a single or multiple preformed amino acids containing multi-modal, multi-chelated metal, multi-dye imaging agents, or combinations of these, on the side chains of resultant peptides. These imaging amino acids or peptides may be conjugated directly, or activated, or attached to linkers to which targeting groups, such as peptides, proteins, antibodies, aptamers, or small molecule inhibitors, may be conjugated in the final steps of the synthesis to form a wide variety of TMIAs.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: April 7, 2020
    Assignee: Rochester Institute of Technology
    Inventors: Hans F. Schmitthenner, Stephanie Beach, Taylor Barrett, Chelsea Weidman
  • Patent number: 10603352
    Abstract: The present disclosure provides a drug formulation for hepalatide, comprising hepalatide and a buffer salt, and containing or not containing an osmotic regulator and/or an excipient.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: March 31, 2020
    Assignee: Shanghai HEP Pharmaceutical Co., Ltd.
    Inventor: Hongli Liu
  • Patent number: 10597634
    Abstract: The invention provides a device and the use thereof in a cell experiment in vitro. This device has a polydopamine layer-carboxymethyl chitosan layer-peptide layer structure, which is capable of regulating behaviors of human pluripotent stem cells and is useful in cell culture or a cell experiment in vitro.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: March 24, 2020
    Assignee: Peking University School and Hospital of Stomatology
    Inventors: Shicheng Wei, Ping Zhou, Xiaohong Zhang, Yongliang Li, Mengke Wang
  • Patent number: 10576124
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: March 3, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Patent number: 10543249
    Abstract: A pharmaceutical composition for a sustained release of peptide therapeutics, in particular for a sustained release compatible with therapeutic treatments of at least two months. In an embodiment, the composition comprises lanreotide as an active agent, a hydrosoluble co-solvent, and water with the pH of the composition being from 4.0 to 7.5.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: January 28, 2020
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Ruth Bielsa Guivernau, Roland Cherif-Cheikh, Julie Fournes, Daniel Martinez Lorente, Anne Petit, Joël Richard
  • Patent number: 10526372
    Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: January 7, 2020
    Assignee: ALBA THERAPEUTICS CORPORATION
    Inventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco